FDA Generative AI Medical Device Regulation: What QA and Regulatory Leaders Need to Know

Pharma Now analyzes the FDA’s new discussion paper on regulating generative AI-enabled medical devices, describing a proposed two-axis risk framework and competency-based premarket evaluation model. The piece explains how the FDA’s approach could reshape governance standards for clinical AI, with implications for validation, lifecycle oversight, and quality assurance in regulated healthcare environments.